Our infectious disease services bring you “mini-organs in a dish” derived from human patients (healthy and diseased) to help predict host–pathogen responses with biological fidelity.
Our end-to-end process transforms patient biopsies into validated, expandable models that accelerate drug discovery and translational research.
Enhance translational relevance from the start of your drug development process. With deep expertise in organoid monolayers and 3D co-culture models integrating multiple cell types, we enable robust, physiologically relevant assays to identify and validate promising leads for clinical progression.
